Treating fibroblasts of PD patients with Miro1 Reducer rescues the phenotype of Miro1 accumulation on damaged mitochondria, and applying Miro1 Reducer to human neuron and fly models of PD ameliorates Parkinson’s relevant phenotypes, without affecting Miro1’s overall GTPase activity or other mitochondrial proteins including Miro2, Mitofusin, OPA1, VDAC, and ATP5β (Hsieh et al., 2019). This evidence concerns the gene RHOT1 and Parkinson disease.